JonesTrading analyst Sean Kim PhD reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report) today and set a price target of $18.00. The company’s shares opened today at $5.65.
Kim PhD covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, Trevi Therapeutics, and Phathom Pharmaceuticals. According to TipRanks, Kim PhD has an average return of 34.4% and a 62.16% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ocuphire Pharma with a $19.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.50 and a one-year low of $1.78. Currently, Ocuphire Pharma has an average volume of 206.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Read More on OCUP:
